Experts Highlight New Dermatological Treatments, Importance of Clinical Trial Diversity
Experts at the Skin of Color Update discussed recent FDA approvals for dermatology treatments, emphasizing the importance of clinical trial diversity. Key approvals included roflumilast and tapinarof for psoriasis, roflumilast for seborrheic dermatitis, and roflumilast for atopic dermatitis. Additionally, biologic therapies such as bimekizumab for psoriasis, secukinumab for hidradenitis suppurativa, and nemolizumab for prurigo nodularis were highlighted. The FDA is developing a diversity action plan to ensure more inclusive clinical trials.
Related Clinical Trials
Reference News
Experts at the Skin of Color Update discussed recent FDA approvals for dermatology treatments, emphasizing the importance of clinical trial diversity. Key approvals included roflumilast and tapinarof for psoriasis, roflumilast for seborrheic dermatitis, and roflumilast for atopic dermatitis. Additionally, biologic therapies such as bimekizumab for psoriasis, secukinumab for hidradenitis suppurativa, and nemolizumab for prurigo nodularis were highlighted. The FDA is developing a diversity action plan to ensure more inclusive clinical trials.
At the Skin of Color Update 2024 conference, Valeria M. Harvey discussed the lack of diversity in clinical trials, emphasizing the need for inclusive marketing and diverse principal investigators. The FDA's draft guidance on Diversity Action Plans aims to increase underrepresented group enrollment in clinical studies. Andrew F. Alexis highlighted recent dermatology advances, including approvals for topical therapies like roflumilast and tapinarof, and ongoing trials for biologics in atopic dermatitis treatment.